DelveInsight’s, “PD-1 Non-Small Cell Lung Cancer Pipeline Insight” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in PD-1 Non-Small Cell Lung Cancer pipeline landscape. It covers the PD-1 Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the PD-1 Non-Small Cell Lung Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive PD-1 Non-Small Cell Lung Cancer pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight’s comprehensive PD-1 Non-Small Cell Lung Cancer Pipeline Report to explore emerging therapies, key PD-1 Non-Small Cell Lung Cancer Companies, and future PD-1 Non-Small Cell Lung Cancer treatment landscapes @ PD-1 Non-Small Cell Lung Cancer Pipeline Outlook Report
Key Takeaways from the PD-1 Non-Small Cell Lung Cancer Pipeline Report
- In January 2025:- AstraZeneca:- This is a first-time-in-human (FTIH), open-label, multicenter, multi-part, dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics, and efficacy of rilvegostomig (AZD2936) in adult participants with stage III unresectable or stage IV NSCLC. The study includes 4 parts: Part A (dose escalation) and Parts B-E (dose expansion).
- In January 2025:- BioAtla Inc.:- This is a multi-center, open-label, Phase 2 study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3011, a conditionally active biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC), alone and in combination with PD-1 inhibitor in patients with metastatic non-small cell lung cancer (NSCLC).
- In January 2025:- Incyte Corporation:- The purpose of this study is to assess the efficacy and safety of platinum-based chemotherapy with or without INCMGA00012 in participants with metastatic squamous and nonsquamous non-small cell lung cancer (NSCLC).
- In January 2025:- Merck Sharp & Dohme LLC:- The purpose of this study is to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) plus pembrolizumab (MK-3475) in the treatment of adult participants with unresected stage I or II (Stage IIB N0, M0) non-small cell lung cancer (NSCLC).
- In January 2025:- Gilead Sciences- The goal of this clinical study is to compare the study drug, sacituzumab govitecan-hziy (SG), versus docetaxel in participants with advanced or metastatic (cancer that has spread) non-small cell lung cancer (NSCLC).
- DelveInsight’s PD-1 Non-Small Cell Lung Cancer pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for PD-1 Non-Small Cell Lung Cancer treatment.
- The leading PD-1 Non-Small Cell Lung Cancer Companies such as Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma and others.
- Promising PD-1 Non-Small Cell Lung Cancer Therapies such as AZD2936, Pembrolizumab 200 mg, Cisplatin, Carboplatin, Durvalumab (MEDI4736), and others.
Discover how the PD-1 Non-Small Cell Lung Cancer treatment paradigm is evolving. Access DelveInsight’s in-depth PD-1 Non-Small Cell Lung Cancer Pipeline Analysis for a closer look at promising breakthroughs @ PD-1 Non-Small Cell Lung Cancer Clinical Trials and Studies
PD-1 Non-Small Cell Lung Cancer Emerging Drugs Profile
- Zimberelimab: Arcus Biosciences
Zimberelimab is an anti-programmed cell death protein-1 (PD-1) monoclonal antibody being developed by Gloria Biosciences, Arcus Biosciences and Taiho Pharmaceutical Co. for the treatment of various cancers including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma. Based on the results of a phase II trial, zimberelimab was recently approved for marketing in China as treatment for relapsed or refractory classical Hodgkin’s lymphoma. Zimberelimab was in-licensed by Arcus to enable the development of precision combination regimens with full line-of-sight to the commercialization of innovative therapies for all patients who may benefit. The most advanced study with zimberelimab is in Phase III development for the treatment of first-line metastatic non-small cell lung cancer, evaluating zimberelimab in combination with domvanalimab, an anti-TIGIT monoclonal antibody, and etrumadenant, the first and only dual A2a/A2b adenosine receptor antagonist in the clinic.
- PM8002: Biotheus
PM8002 is a bispecific antibody candidate with humanized anti-PD-L1 single heavy-chain variable (VHH) domains fused to an anti-VEGF-A IgG1 antibody containing Fc-silencing mutations. PM8002 had demonstrated a positive safety profile and encouraging antitumor activity presumably through reduced systemic toxicity by enriching anti-VEGF activity into the tumor microenvironment at ASCO Annual Meeting and ESMO Congress 2023. Currently, the drug is in Phase II/III stage of its clinical trial for the treatment of NSCLC.
- RPH075: R-Pharm
R-Pharm’s pembrolizumab biosimilar, known as RPH 075, is a monoclonal antibody classified under antineoplastics, antivirals, and immunotherapies, specifically tumor-agnostic therapies. This biosimilar mimics the action of the originator drug, pembrolizumab, by targeting and antagonizing the programmed cell death 1 (PD-1) receptor on T lymphocytes. By blocking the interaction between PD-1 and its ligands, RPH 075 enhances T-cell mediated immune responses against cancer cells, promoting antibody-dependent cell cytotoxicity and providing a potent means to counteract tumors. Currently, the drug is in Phase I stage of its clinical trial for the treatment of NSCLC.
The PD-1 Non-Small Cell Lung Cancer pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of PD-1 Non-Small Cell Lung Cancer with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for PD-1 Non-Small Cell Lung Cancer Treatment.
- PD-1 Non-Small Cell Lung Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- PD-1 Non-Small Cell Lung Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the PD-1 Non-Small Cell Lung Cancer market.
Get a detailed analysis of the latest innovations in the PD-1 Non-Small Cell Lung Cancer pipeline. Explore DelveInsight’s expert-driven report today! @ PD-1 Non-Small Cell Lung Cancer Unmet Needs
PD-1 Non-Small Cell Lung Cancer Companies
Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma and others.
PD-1 Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
PD-1 Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as
- Monoclonal antibody
- Small molecule
- Peptide
Download DelveInsight’s latest report to gain strategic insights into upcoming PD-1 Non-Small Cell Lung Cancer Therapies and key PD-1 Non-Small Cell Lung Cancer Developments @ PD-1 Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspectives
Scope of the PD-1 Non-Small Cell Lung Cancer Pipeline Report
- Coverage- Global
- PD-1 Non-Small Cell Lung Cancer Companies- Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma and others.
- PD-1 Non-Small Cell Lung Cancer Therapies- AZD2936, Pembrolizumab 200 mg, Cisplatin, Carboplatin, Durvalumab (MEDI4736), and others.
- PD-1 Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- PD-1 Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in PD-1 Non-Small Cell Lung Cancer drug development? Find out in DelveInsight’s exclusive PD-1 Non-Small Cell Lung Cancer Pipeline Report—access it now! @ PD-1 Non-Small Cell Lung Cancer Emerging Drugs and Major Companies
Table of Content
- Introduction
- PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) : Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- PD-1 Non-Small Cell Lung Cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Zimberelimab: Arcus Biosciences
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Drug name: Company name
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- RPH075: R-Pharm
- Preclinical Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) – Collaborations Assessment- Licensing / Partnering / Funding
- PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) – Unmet Needs
- PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) – Market Drivers and Barriers
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/oral-electrolyte-solutions-market